Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
CYCyteir Therapeutics, Inc. logo

Cyteir Therapeutics, Inc. (CYT)

NASDAQ Global Select · Currency in USD
$3.02 ▼ -0.07 (-2.27%)
At close: Mar 15, 4:00 PM ET. Market closed.

Summary

Previous Close
$3.09
Open
$3.03
Day's Range
$3.00 – $3.09
52 Week Range
$1.65 – $3.19
Volume
1,006,884
Avg. Volume
171,443
Market Cap
$108.71M
Beta (5Y Monthly)
0.10
PE Ratio (TTM)
--
EPS (TTM)
-$1.25
Earnings Date
--
Forward Dividend & Yield
$0.52 (17.22%)
Ex-Dividend Date
Nov 6, 2015
1y Target Est
$2.00

Profile: Cyteir Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
46
CEO
Markus F. Renschler
Website
cyteir.com

Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies.

Earnings

DateEst.Actual
Mar 28, 2024-$0.20-$0.25Miss
Nov 6, 2023–-$0.10
Aug 7, 2023-$0.32-$0.24Beat
May 10, 2023-$0.27-$0.35Miss
Mar 23, 2023-$0.34-$0.25Beat
Nov 7, 2022-$0.41-$0.31Beat

Analyst view

Consensus price target
$2.00 ▼ -33.8%
Range $2.00 – $2.00
Rating: Buy
Buy 40% · Hold 20% · Sell 40%

Get free alerts on CYT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.